Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. - Wikidata - wikimedia - TriplyDB

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

http://www.wikidata.org/entity/Q51491852

about

Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality RAGE: a new frontier in chronic airways disease Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis.Advanced glycation end-products and their receptor-mediated roles: inflammation and oxidative stress.Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study.Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.Endogenous secretory receptor for advanced glycation end products and chronic kidney disease in the elderly population.Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function.Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes.Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat Clinical study of advanced glycation end products in egyptian diabetic obese and non-obese patients.The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies.Advanced Glycation End Products, Inflammation, and Chronic Metabolic Diseases: Links in a Chain?Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.Regulation of Receptor for Advanced Glycation End Products (RAGE) Ectodomain Shedding and Its Role in Cell Function.Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study.sRAGE in septic shock: a potential biomarker of mortality AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women.Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects.RAGE expression and NF-kappaB activation attenuated by extracellular domain of RAGE in human salivary gland cell line.Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women.Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients.Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.

P2860

Q26747425-3832FAFE-4EBD-45F9-B01E-E717B4943B0C Q26781477-38834020-6E4A-4469-ADD3-CB1BA7528489 Q26859793-37BFC6B9-E049-45A1-8C59-03522232A938 Q27025295-6CF9437D-6EB5-4EE4-BED9-6B9B98F291B5 Q30412055-BB4B26D3-3E60-4CFF-A522-237DA4B6D17F Q30426453-0EA95E70-5D16-42A8-89C2-CB8E8B642990 Q33592848-CEFACF12-DF3D-45BC-8AE4-822AF83BF11C Q34564061-89F551F5-DBC0-451B-B04E-0630E485918C Q34724954-871332C6-D405-434C-ABDD-2277A7688489 Q34728267-8F84194F-9F85-49AA-A3F6-4C096EC5E4DC Q34949171-F1890550-31BB-4123-A84D-AC696C7B9691 Q34987953-A918D958-7797-41A8-B7C0-874CA0E02FE0 Q35048039-D24104AE-D0CE-43FF-BF62-B1BA995D4196 Q35093747-273ABCE6-A348-4E5A-82D8-B4528037E938 Q35160764-D25836CF-17F8-494B-98E5-546FF59997FA Q35844102-EE73DBB9-6082-4DE3-BBD6-1809ACF14C59 Q36458415-6C2EB75D-7C2A-43DE-B901-773D8C351241 Q36735682-CB1D0E16-9FEC-4011-AD20-705B12F3E4C9 Q36857011-D149CA0D-7FF1-410E-85E6-906C557009DF Q36969021-24253921-B94C-4711-84FC-C42A852E5BB8 Q37152947-D626C3A7-4494-4EBF-AB7E-620F0A54E5D0 Q37541529-0C9727E2-A855-4850-B0EB-12B5E4F2003D Q38234313-84FB4EED-A3CD-4A90-B181-6F40CCB579D7 Q38254631-994CF689-8C8D-41EF-8ABF-D0FA96715615 Q38686477-42D8DF11-CF1C-49F3-BFAD-FCD1194FABD9 Q38743691-F7F3ACC1-E019-4118-BC4E-7F796557098D Q38782723-D6FE12F2-5923-4400-87A5-29433B611F30 Q38853305-862D9A3C-3CF6-4412-B060-00311E37F99A Q39052240-EEFD06C3-77F4-4D6A-ABBE-A696F32CCB57 Q39313922-EE7C6DAB-1A7E-44AC-8E80-AEB7F9036483 Q39492253-7ABAB429-D4EC-4EC8-B1EA-1098B59E4BB5 Q39711731-50E72C08-FA1A-4770-9C6D-753611DC51C1 Q39826749-C0FC59DC-1EE9-48C2-A166-602B572BADF4 Q41582432-C05CE5F4-5676-4096-8633-3573DC7998FF Q41789363-9C9D270B-FDC0-433F-880C-3016D8DBD81E Q42115221-D37A1896-EDE8-44ED-8DAA-DDC553E72E80 Q42176457-7918A559-8469-4535-A53B-B2B36F5BD157 Q42256397-4D0693E8-C073-40E8-BB3B-B6DDFFD6FFEF Q42589786-727B8759-8E9E-4436-87D2-4EC676448BF1 Q43742322-8F2491F5-249D-41E0-8A85-86AED3D8B209

P2860

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

http://www.wikidata.org/entity/Q51491852

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Positive association between s ...... ducts in nondiabetic subjects.

@en

Positive association between s ...... ducts in nondiabetic subjects.

@nl

type

label

Positive association between s ...... ducts in nondiabetic subjects.

@en

Positive association between s ...... ducts in nondiabetic subjects.

@nl

prefLabel

Positive association between s ...... ducts in nondiabetic subjects.

@en

Positive association between s ...... ducts in nondiabetic subjects.

@nl

P1433

Q51491852-260F2249-F959-4A98-8938-F265E1D96B2A

P1476

Q51491852-69F2687D-40E2-4623-AD0B-56C4D357DC45

P2093

Q51491852-0A483D3E-6C73-4856-8990-7A093882C1CA

Q51491852-1159C54F-F151-4018-AED5-4413DA54275C

Q51491852-135B1D36-F08F-44CA-93F2-6BC7DD4E64AE

Q51491852-25069BDA-B520-44C0-9247-44F928CEEE16

Q51491852-3A98EAB8-E786-48AF-9A22-2A0D788B7A8F

Q51491852-3E1538E4-5DA4-4462-A5D1-3F57E67C91ED

Q51491852-4396BB0E-D8E1-4F9A-85F7-8832E3A0E47E

Q51491852-66499ADF-6D52-456A-A5CC-13AD7FD2B31B

Q51491852-7BC9242D-D81E-47CF-A3A1-71474CCB25DD

Q51491852-96FFEC8D-6BA5-482F-9132-908BAF87BAAB

P304

Q51491852-502DCBBA-7C5A-45B4-9AE8-DE623100094E

P31

Q51491852-5B5F9883-D1C5-4E48-B144-D8B152197522

P356

Q51491852-D4DE1495-90A7-4ABA-B065-C73463457983

P433

Q51491852-7437B0B9-65C9-4C87-A07D-0EE9933E7397

P478

Q51491852-BF5C165D-A60C-463F-BBF5-A08B64E8C007

P577

Q51491852-F6617E94-B8E1-4F68-B96B-5851A9F43666

P698

Q51491852-CE537785-9B75-4902-A06A-AB80DB7AA4B0

P356

J.METABOL.2006.05.007

P1433

P1476

Positive association between s ...... ducts in nondiabetic subjects.

@en

P2093

Asuka Hino

http://www.w3.org/2001/XMLSchema#string

Hisashi Adachi

http://www.w3.org/2001/XMLSchema#string

Katsuhiko Takenaka

http://www.w3.org/2001/XMLSchema#string

Kazuo Nakamura

http://www.w3.org/2001/XMLSchema#string

Kumiko Furuki

http://www.w3.org/2001/XMLSchema#string

Masayoshi Takeuchi

http://www.w3.org/2001/XMLSchema#string

Mika Enomoto

http://www.w3.org/2001/XMLSchema#string

Sho-ichi Yamagishi

http://www.w3.org/2001/XMLSchema#string

Takanori Matsui

http://www.w3.org/2001/XMLSchema#string

Tsutomu Imaizumi

http://www.w3.org/2001/XMLSchema#string

P304

1227-1231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.METABOL.2006.05.007

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16919543

http://www.w3.org/2001/XMLSchema#string